TGTX (TG Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by TGTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-14 | Laurence N Charney | Director | Sell | — | — |
| 2026-08-07 | Laurence N Charney | Director | G | — | — |
| 2026-08-07 | Laurence N Charney | Director | G | — | — |
| 2026-06-15 | Sagar Lonial | Director | A | — | — |
| 2026-06-15 | Yann Echelard | Director | A | — | — |
| 2026-06-15 | DANIEL HUME | Director | A | — | — |
| 2026-06-15 | Laurence N Charney | Director | A | — | — |
| 2026-06-15 | Kenneth Hoberman | Director | A | — | — |
| 2026-01-29 | Laurence N Charney | Director | G | — | — |
| 2026-01-09 | MICHAEL S WEISS | CEO | A | — | — |
| 2026-01-09 | Sean A Power | CFO | A | — | — |
| 2025-11-25 | Yann Echelard | Director | Sell | — | — |
| 2025-11-07 | MICHAEL S WEISS | CEO | G | — | — |
| 2025-09-12 | Sagar Lonial | Director | Sell | — | — |
| 2025-06-16 | Kenneth Hoberman | Director | A | — | — |
| 2025-06-16 | Laurence N Charney | Director | A | — | — |
| 2025-06-16 | Yann Echelard | Director | MIXED | — | — |
| 2025-06-16 | DANIEL HUME | Director | A | — | — |
| 2025-06-16 | Sagar Lonial | Director | A | — | — |
| 2025-03-18 | DANIEL HUME | Director | G | — | — |
| 2025-03-11 | Laurence N Charney | Director | G | — | — |
| 2025-01-30 | Sean A Power | CFO | A | — | — |
| 2025-01-30 | MICHAEL S WEISS | CEO | A | — | — |
| 2025-01-07 | Sean A Power | CFO | Sell | — | — |
| 2024-11-12 | Sagar Lonial | Director | Sell | — | — |
| 2024-11-12 | Laurence N Charney | Director | MIXED | — | — |
| 2024-11-07 | Yann Echelard | Director | Sell | — | — |
| 2024-06-20 | Laurence N Charney | Director | A | — | — |
| 2024-06-20 | DANIEL HUME | Director | A | — | — |
| 2024-06-20 | Yann Echelard | Director | A | — | — |
| 2024-06-20 | Sagar Lonial | Director | MIXED | — | — |
| 2024-06-20 | Kenneth Hoberman | Director | A | — | — |
| 2024-03-15 | Sagar Lonial | Director | Sell | — | — |
| 2024-03-13 | Laurence N Charney | Director | Sell | — | — |
| 2024-01-08 | Laurence N Charney | Director | Sell | — | — |
| 2024-01-08 | MICHAEL S WEISS | CEO | A | — | — |
| 2024-01-05 | Sean A Power | CFO | MIXED | — | — |
| 2023-09-29 | Kenneth Hoberman | Director | A | — | — |
| 2023-09-29 | DANIEL HUME | Director | A | — | — |
| 2023-09-29 | Laurence N Charney | Director | A | — | — |
| 2023-09-29 | Yann Echelard | Director | A | — | — |
| 2023-09-29 | Sagar Lonial | Director | A | — | — |
| 2023-08-14 | MICHAEL S WEISS | CEO and President | Buy | — | — |
| 2023-06-26 | Sagar Lonial | Director | Sell | — | — |
| 2023-06-05 | Sean A Power | Chief Financial Officer | Sell | — | — |
| 2023-03-14 | MICHAEL S WEISS | CEO and President | A | — | — |
| 2023-03-14 | Sean A Power | Chief Financial Officer | A | — | — |
| 2023-01-06 | Laurence N Charney | Director | Sell | — | — |
| 2023-01-06 | Yann Echelard | Director | Buy | — | — |
| 2022-07-22 | DANIEL HUME | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO | 24,212,300 | — |
| — | 10%+ Owner | 12,629,868 | — |
| — | 10%+ Owner | 7,614,855 | — |
| — | CFO | 798,111 | — |
| — | Director | 279,653 | — |
| — | Director | 223,816 | — |
| — | Director | 192,748 | — |
| — | Director | 168,640 | — |
| — | Director | 125,949 | — |
| — | Director | 109,633 | — |
| — | Director | 94,061 | — |
| — | Director | 68,550 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TGTX quote page; the site-wide leaderboard is on the insider transactions hub.